ObsEva Annual Report 2021
ObsEva SA has released its Annual Report 2021 to Shareholders, detailing the company's developments in women's reproductive health.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ObsEva SA has released its Annual Report 2021 to Shareholders, detailing the company's developments in women's reproductive health. The report can be accessed via their website. ObsEva is focused on developing therapies for uterine fibroids, endometriosis, and preterm labor. The company utilizes strategic in-licensing and disciplined drug development, and is listed on both NASDAQ under the ticker OBSV and the SIX Swiss Exchange as OBSN.
Positive
- Establishment of a late-stage clinical pipeline focused on women's reproductive health.
- Strategic in-licensing and disciplined drug development enhance potential for successful therapies.
Negative
- None.
Details
News Market Reaction – OBSV
The recorded move for OBSV in the trading session of this news was +0.67%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
Geneva, Switzerland and Boston, MA – March 31, 2022 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today published its Annual Report 2021 to Shareholders.
The Annual Report 2021 to Shareholders may be found in the financial section of the Company's website, [here]. To access the Annual Report 2021 to Shareholders directly, please click [here].
About ObsEva
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment of uterine fibroids, endometriosis, and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is traded under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.
For further information, please contact:
CEO Office Contact:
Shauna Dillon
shauna.dillon@obseva.ch
+41 22 552 1550
Investor Contact:
Katja Bührer
Katja.buhrer@obseva.com
+1 (917) 969-3438
###
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.